Treatment of testicular cancer: a new and improved model.
about
Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the LiteratureHuman germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin.Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study GroupCarboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma.Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.Treatment of disseminated non-seminomatous testicular cancer: the European experience.Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial.Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumoursEngineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancyRandomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review.Current status and future perspectives in the treatment of advanced testicular cancer.Intensive chemotherapy as salvage treatment for solid tumors: focus on germ cell cancer.Synthesis and characterization of potential iron-platinum drugs and supplements by laser liquid photolysisPhase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of CaRecent advances in management of patients with platinum-refractory testicular germ cell tumors.Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.Long-term effects on sexual function and fertility after treatment of testicular cancerRapid progression of a germ cell tumor encasing the inferior vena cava and aorta following a radical orchiectomyNanoparticle encapsulation of mitaplatin and the effect thereof on in vivo propertiesDNA crosslinking damage and cancer - a tale of friend and foe.Treatment-related cardiovascular late effects and exercise training countermeasures in testicular germ cell cancer survivorship.Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.Application of liposomal technologies for delivery of platinum analogs in oncology.Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.HER-2/neu expression in germ cell tumours.Cisplatin-induced renal toxicity magn…ified: role of magnesium deficiency in AKI onset.Investigational targeted therapies for the treatment of testicular germ cell tumors.Platinum-refractory germ cell tumors: an update on current treatment options and developments.Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation.Scrotal Involvement with Testicular Nonseminomatous Germ Cell TumourCisplatin-induced alterations in the functional spermatogonial stem cell pool and niche in C57/BL/6J mice following a clinically relevant multi-cycle exposure.Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer.Symptom burden in long-term germ cell tumor survivors.DNA repair capacity and cisplatin sensitivity of human testis tumour cells.Hotspot TERT promoter mutations are rare events in testicular germ cell tumors.Osteolytic bone destruction resulting from relapse of a testicular tumour 23 years after inguinal orchiectomy and adjuvant chemotherapy: a case report.Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials
P2860
Q26766244-81CDC87A-95D0-4D1C-AFC4-A85C7BCAFF4EQ30304276-78656526-824F-4DE8-BFA2-61FB92FDD50FQ33344289-5A884A0B-6BB9-407F-B15A-5776E69F31DDQ33403094-1EB034EA-D3E5-45E8-9D53-0A6EAF91ABDFQ33591683-F4E2A94A-7A90-4D67-B471-904FBABA6203Q33788904-3EF5027C-91EC-4D30-81D0-2A9E7391B3F0Q33877463-DEAA3EBB-38B3-4B45-8D8B-FDDB507BAF9FQ33956190-551312CE-D3FD-47C0-A509-3B2407E91926Q34104101-CD5EF44B-1D70-4D95-B76A-0702B3A9AF43Q34136937-EFE4015D-2CBA-4E20-9FD7-64182D3F945AQ34298244-3CF79E1B-9801-43AA-A04D-0932E62C721BQ34612225-4C97DAD6-BCEC-47C8-A015-65EBF3387C73Q34886445-0B7E3308-B374-4393-B73B-BC8F0EA4F466Q35033335-3702A32B-8B43-4228-870C-3789074EDF89Q35866351-9C6B47D3-5579-4DB8-9DA3-8E295C6DD6ECQ36114922-0D3E41F7-51EB-4303-9162-918801AC1CBEQ36389456-8BC88525-C635-4607-AD35-B6AD1BAB8D95Q36573543-706AACEB-28E5-496E-9CBF-DD460374C469Q36617695-67826E6D-03B8-4088-896F-DABDEF86880CQ37034624-8FA4DE6D-9A8D-479D-BDBA-ABA25120A298Q37042860-F16B7320-0806-4CF6-A020-0C20566E3FCBQ37127343-F535E15C-A602-4A5B-A7BA-C9B60905F45FQ37251177-5E0AEEA9-66A4-49CC-B0A7-A117A75D5D5EQ37288442-4CBCFFF0-BF27-4459-AF06-491FD1990EBCQ38136184-104489CF-D1FE-43A3-AB15-037BB054D231Q38282540-6DFB2422-304E-4481-8A07-1F6F9559EED7Q38455404-B9228232-C480-4699-8AA4-A37FB64E2713Q38618836-6AAD9446-728F-4610-9FAF-3575820EE99FQ38861307-750D99F6-A831-4ADD-9637-D4A5366981FAQ38906007-9BAC871C-14C0-4171-86EF-369BB430603EQ38983107-EC5A24F7-AC0A-4915-ADE0-18817B9395C9Q39004119-A637C5BB-5559-4AED-9D04-916849ABE011Q39007526-156DFF0A-0E40-4BE5-B815-6100F5667CAFQ39051290-3D8C0010-FE6D-48E6-81E8-9D1BD69D21BFQ40000083-6D8F2641-6DD4-4EDD-9575-762468DD4680Q41118556-010934B8-05F0-4712-91BA-FF325C8251F3Q41121314-FDD5297C-760D-4E67-9B8C-3DD35357378DQ41156947-B64D1BE6-FFBE-4253-AAE4-100A6B6FBF12Q41829400-539CF68F-8D8A-4D87-A06A-5063D215E41CQ41889294-404BB095-527D-4CDD-83DC-9D977A02CD70
P2860
Treatment of testicular cancer: a new and improved model.
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Treatment of testicular cancer: a new and improved model.
@ast
Treatment of testicular cancer: a new and improved model.
@en
Treatment of testicular cancer: a new and improved model.
@nl
type
label
Treatment of testicular cancer: a new and improved model.
@ast
Treatment of testicular cancer: a new and improved model.
@en
Treatment of testicular cancer: a new and improved model.
@nl
prefLabel
Treatment of testicular cancer: a new and improved model.
@ast
Treatment of testicular cancer: a new and improved model.
@en
Treatment of testicular cancer: a new and improved model.
@nl
P1476
Treatment of testicular cancer: a new and improved model.
@en
P2093
L H Einhorn
P304
P356
10.1200/JCO.1990.8.11.1777
P407
P577
1990-11-01T00:00:00Z